MYC and Miyoshi myopathy: Specifically, IKZF1/3 are degraded via activation of CRBN upon IMiD treatment, thereby triggering MM cell growth inhibition.4, 5 We here observed that ACY1215 markedly downregulated IKZF1, IRF4 and c-Myc in a dose-dependent manner (Figure 4c).